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Abstract The TolC structure has unveiled a common mecha-
nism for the movement of molecules, large and small, from the
bacterial cell cytosol, across two membranes and the intervening
periplasm, into the environment. Trimeric TolC is a remarkable
cell exit duct that di¡ers radically from other membrane pro-
teins, comprising a 100-A! long K-barrel that projects across the
periplasmic space, anchored by a 40-A! long L-barrel spanning
the outer membrane. The periplasmic entrance of TolC is closed
until recruitment by substrate-speci¢c translocases in the inner
membrane triggers its transition to the open state, achieved by
an iris-like ‘untwisting’ of the tunnel K-helices. TolC-dependent
machineries present ubiquitous exit routes for virulence proteins
and antibacterial drugs, and their conserved structure, speci¢-
cally the electronegative TolC entrance constriction, may
present a target for inhibitors of multidrug-resistant pathogens.
( 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. TolC: a role in bacterial protein export and the e¥ux of
small toxic molecules
The envelope protein TolC was named many years ago
when its loss by mutation was seen to confer tolerance to
speci¢c colicins and bacteriophage [1^3], and to ‘pleiotropi-
cally’ increase bacterial sensitivity to environmental stresses
like detergents, bile salts and organic solvents [4^7]. While
TolC is exploited ‘passively’ as a bacterial cell entry receptor
by the phage and colicins, it plays an active and central role in
the expulsion of a plethora of molecules from Gram-negative
bacteria such as Escherichia coli and Pseudomonas aeruginosa
[5,8,9].
It was ¢rst found that TolC is needed for the atypical ex-
port of large proteins, including toxins and enzymes directed
at mammalian hosts during infection [10^13]. Gram-negative
bacteria have two cell membranes, cytoplasmic (inner) and
outer, separated by an intervening periplasmic space [14]. Pro-
teins destined for the cell surface or the external medium, for
example during the assembly of adhesion pili [15] or £agella
[16], or delivery of virulence e¡ector proteins into mammalian
cells, are typically secreted by large multiprotein assemblies
that either span the periplasm or establish two-step mecha-
nisms employing periplasmic intermediates [15^17]. TolC-de-
pendent (‘type I’) export bypasses the periplasm and yet re-
quires only outer membrane TolC acting with an inner
membrane translocase of two proteins, a tra⁄c ATPase and
an ‘adaptor’ protein [10,12,18]. Our work has focussed on
type I export of the 110-kDa E. coli hemolysin (HlyA) [19],
but the same process exports many toxins, proteases and li-
pases [20] from pathogens of humans, animals and plants, and
also substrates like glycanases from plant-nodulating bacteria
[21,22]. The export signal in these proteins is uncleaved and
located at the extreme C-terminus [23,24].
TolC was subsequently also shown to have an active part in
the e¥ux of small noxious molecules like detergents, but in
the last few years it has achieved wider prominence as its
e¥ux substrates were found to include a wide range of anti-
bacterial drugs [25,26]. This established TolC as a key player
in the growing problem of multidrug resistance in pathogenic
bacteria. As in protein export, the e¥ux of antibacterial drugs
and other small inhibitors involves TolC cooperating with an
inner membrane translocase, and this too comprises an adap-
tor protein and a protein providing energy, in this case usually
from proton antiport [25]. Bacteria typically have many e¥ux
pumps with broad speci¢cities. For example, while E. coli
AcrAB-TolC determines resistance to many antibiotics, dyes,
detergents, fatty acids, bile salts and organic solvents [5^7,26],
EmrAB-TolC expels hydrophobic uncouplers of oxidative
phosphorylation, organomercurials and antibacterial drugs
like nalidixic acid and thiolactomycin [27].
2. TolC ^ the key to understanding the protein export and drug
e¥ux mechanisms
From biochemical studies we knew that protein export was
e¡ected by recruitment of TolC by substrate-laden inner mem-
brane translocases [28] (see later). Nevertheless, it was a mys-
tery how events at the inner membrane were coupled, without
periplasmic intermediates, to passage through what was imag-
ined to be a simple outer membrane porin-like channel. Elec-
tron microscopy of two-dimensional crystals [12] intimated
that trimeric TolC might have a novel single transmembrane
pore and perhaps an additional domain that could contribute
to a periplasmic bypass. But it was the high-resolution crystal
structure which revealed vividly how TolC could allow ‘direct’
passage of proteins and drugs from the cytosol out of the cell
[29].
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3. A periplasmic K-barrel anchored by a L-barrel spanning the
outer membrane
X-ray crystallography [29] at 2.1-AS resolution revealed the
TolC homotrimer as a 140-AS long cylinder which is made up
of a 100-AS long K-helical barrel (the ‘tunnel domain’) projec-
ting through the periplasmic space and anchored in the outer
membrane by a 40-AS long L-barrel channel (Fig. 1). This
TolC ‘channel-tunnel’ presents a hollow conduit extending
from near the inner membrane to the cell exterior. Through-
out the outer membrane channel and most of the contiguous
tunnel the accessible interior diameter of the single pore is
19.8 AS average. Three TolC protomers each contribute four
L-strands to the single 12-strand outer membrane L-barrel, an
architecture unknown in other bacterial membrane [29] pro-
teins (Table 1). This channel is constitutively open to the
surrounding medium, and it does not have an inward folded
extracellular loop that typically constricts channel-forming
proteins [31,32], or a plug domain like that of the large L-bar-
rels of FhuA and FepA [33,34].
The periplasmic K-barrel comprises 12 K-helices (four from
each monomer) that follow a left-handed superhelical twist
and pack in an antiparallel arrangement [29]. These tend to
be underwound in the upper half compared to helices in a
conventional two-stranded coiled coil, enabling the helices to
lie on the surface of a cylinder. The 12 helices pack laterally
side-by-side and form two separate interfaces, stabilised by an
intermeshing of side-chain (‘knobs-into-holes’ packing [35]).
In the lower half of the K-barrel neighbouring helices form
six pairs of regular two-stranded coiled coils, but one from
each monomer folds inwards at the end of the tunnel (Fig. 1).
This constricts the entrance to establish a resting closed state,
with an e¡ective diameter of approximately 3.9 AS [29,30]. This
constriction has to be opened for substrate access.
TolC homologues are ubiquitous among Gram-negative
bacteria, and already nearly a hundred have been identi¢ed
[36^38]. E. coli TolC can act in both protein export and in-
hibitor e¥ux, but typically bacteria have multiple system-spe-
ci¢c homologues [38]. Although these homologues can vary in
length by over 100 amino acids [37,38], this is due primarily to
extensions at the periplasmic N- and C-termini and gaps or
insertions either in the equatorial domain outside the K/L
barrel core structure, or the extracellular loops. The K-helices
and L-strands of the channel-tunnel structure do not vary
substantially in length, and deletions or insertions are poorly
tolerated [39]. Sequence divergence is evident, correlating with
function in export or e¥ux, and few amino acids are well
conserved, but these conserved residues occur at structurally
signi¢cant points like the entrance sequence, and highlight
conservation of the basic fold [37,38].
4. Assembly of the TolC-dependent machineries
In both the protein export and drug e¥ux machineries,
TolC interacts with an inner membrane translocase of two
inner membrane proteins, an energy source and an adaptor
protein (Fig. 2). The translocase is assembled constitutively
[28,40], i.e. in the absence of substrate and TolC, and in
each system it provides substrate speci¢city and energy.
TolC is an integral part of the machinery [10,12] ; when it is
Fig. 1. The structures of TolC and other E. coli outer membrane (OM) proteins. Each outer membrane protein is viewed from above the lipid
bilayer (upper) and through the plane of the membrane (lower). Colours indicate protomers. The monomeric OmpA forms the smallest L-barrel
of eight L-strands [61], the large L-barrels of the iron siderophore transporters FhuA and FepA [33,34] comprise 22 L-strands, while in trimeric
porins each monomer forms a L-barrel of 16 (e.g. OmpF) or 18 (e.g. LamB) L-strands [59,60].
Table 1
Structural properties of TolC and other outer membrane proteins
Properties TolC OmpF FepA OmpA
Length (AS ) 140 35 70 57
Radius (AS ) 17.5 15.5 19.9 13
Constriction diameter (AS ) 3.9 11 n/a n/a
Number of pores 1 3 n/a 1
Number of monomers 3 3 1 1
L strands per monomer 4 16 22 8
Conductance (pS) 80 840 n/a n/a
Conductances in picoSiemens are measured in 1 M KCl or NaCl.
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deleted from the hemolysin export system there is no residual
substrate passage to the periplasm or from spheroplasts
[12,25,28]. TolC must be recruited by each substrate-laden
translocase.
What are the translocase components? In type I protein
export, the translocase contains a membrane tra⁄c ATPase
[41^43], exempli¢ed by the homodimeric 707-residue hemoly-
sin B (HlyB), which is predicted to have an N-terminal do-
main encompassing six transmembrane helices, fused to a c.
250 residue C-terminal ATPase domain in the cytosol [18,44].
The e¥ux systems have one of several types of energy-provid-
ing protein [5,8,19], either a proton antiporter or ATP-binding
protein. The 3.5-AS structure of the E. coli AcrB [45] has re-
vealed that, unlike the protein export ATPases, the trimeric
proton antiporter has a large periplasmic domain, of length
70 AS and diameter 80 AS , which comprises two large hydro-
philic loops from each monomer. From the top, AcrB resem-
bles a funnel, with the protomers (each 1049 residues) appear-
ing interlocked by three hairpin structures protruding from
one protomer into the next. The transmembrane region,
length 50 AS and diameter 100 AS , comprises 36 K-helices, 12
from each protomer. Interactions between protomers are re-
stricted to single K-helices from each neighbour so that the
transmembrane domain appears as a chamber with an open-
ing at the ‘cytoplasmic’ side of the membrane [45]. Protein
export and drug e¥ux systems have a common adaptor pro-
tein (Fig. 2). Adaptor proteins have a similar size and hydro-
pathy pro¢le [36,37], and biophysical and electron microscopy
studies of AcrA predict an extended oligomeric structure [46].
The 478-residue export adaptor HlyD is predicted to have a
small N-terminal cytosolic domain (residues 1^59) connected
by a single transmembrane helix to a large periplasmic coiled-
coil domain (residues 81^478) [36,37]. Some drug e¥ux adap-
tors are also predicted to be anchored in the inner membrane
by a transmembrane helix, e.g. EmrA, but others, e.g. AcrA,
are not, and membrane interaction may be favoured by an
N-terminal lipid modi¢cation.
Cross-linking shows that both the translocase components
HlyB and HlyD can interact independently with the HlyA
substrate in vivo [28], and evidence supports the possibility
that the initial engagement involves the export signal [47].
Recruitment of TolC by these translocases is clearly a central
event in the mechanism and in vivo cross-linking shows that
during protein export it is mediated by the adaptor (HlyD)
periplasmic domain [28], putatively by coiled-coil interactions.
This periplasmic interaction is triggered by substrate binding
at the cytoplasmic face of the translocase, but the initial en-
gagement, the ‘signal recognition’ is not su⁄cient for export.
A distinct subsequent step requires transduction of the bind-
ing signal to trigger recruitment of TolC, speci¢cally involving
the small (38-residue) N-terminal cytosolic domain of the
adaptor [48]. This domain comprises a conserved potential
amphipathic helix followed by a group of charged residues.
When this charged cluster alone is deleted, the substrate is still
engaged by the adaptor (and tra⁄c ATPase) but export and
TolC recruitment are disabled [48,49]. These data suggest that
interaction by protein substrates at the cytosolic face of the
export machinery involves initial engagement at the cytosolic
ATPase domain, with interaction extending to the adaptor
cytosolic domain, possibly augmenting the initial engagement
and also mediating transduction of the substrate-binding sig-
nal to the large coiled coil of the TolC-recruiting adaptor
periplasmic domain.
The AcrB structure [45] indicates that the top of the AcrB
periplasmic domain might touch the TolC K-barrel domain,
six vertical hairpins, at the apex of the AcrB trimer could
dock with the six K-helix turn K-helix structures at the bottom
of TolC, especially as the diameters are about the same. Such
a direct interaction between TolC and the energy component
Fig. 2. Assembly of TolC-dependent machineries. Models of protein
export (top) and drug e¥ux (bottom) achieved by reversible interac-
tion of TolC or a homologue with substrate-speci¢c inner mem-
brane (IM) complexes (translocases). These contain a common
adaptor protein and an energy-providing protein, in export a tra⁄c
ATPase and in drug e¥ux most commonly a proton antiporter (the
¢gure shows AcrB, which has a substantial periplasmic domain). In
this way a contiguous exit route is assembled from the cytosol to
the outside environment. In each case it is proposed that a key
event is opening the TolC entrance. The assembly process may in
both cases require the cell proton-motive force, but substrate trans-
location is driven by the speci¢c activities of the translocase,
whether from ATP or proton movement.
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might be stable or not, and might not be possible in the
protein export pathway as the tra⁄c ATPases are not pre-
dicted to have the periplasmic loops. This is also true for
the MFS and ATP-binding cassette (ABC) pumps, as they
too lack a periplasmic domain, and may indicate a di¡erence
in emphasis in adaptor function, with the adaptor protein
AcrA having a principal role in stabilising the AcrB-TolC
docking rather than overt recruitment, as has been proposed
for the export adaptor HlyD [28,49]. This seems to be sup-
ported by our current analyses of the AcrAB/TolC e¥ux sys-
tem, which shows that while the AcrA adaptor has micromo-
lar a⁄nity with each of the AcrB antiporter and TolC, no
binding is detected between these last two proteins in vitro
(Koronakis and colleagues, unpublished), possibly re£ecting
that their interaction needs to be stabilised by AcrA. At this
stage a better understanding awaits further biochemical inves-
tigation and the structure of an adaptor component.
5. Translocation of substrates by the export and e¥ux pumps
The use of chemical uncouplers has suggested that an early
stage requiring the electrochemical potential re£ects assembly
of the complete substrate-bound export complex [50], and that
in the subsequent (post-assembly) stage of export transloca-
tion is driven using ATP hydrolysis by the export ATPase
[50]. In support of this view, ATPase mutations preventing
hydrolysis of bound ATP abolish protein export but not the
assembly of the substrate-engaged HlyB/HlyD/TolC complex
[28,51,52]. It is possible that the large substrate passes through
the translocase in a partially unfolded state, resulting in
‘ratcheted’ translocation driven by ATP hydrolysis, but this
is speculation, especially as no contacts have been de¢ned
between internal regions of the substrate and any of the mem-
brane exporter components. What is known is that once the
protein substrate passes out of the cell the inner and outer
membrane components revert to their resting state, i.e. the
active export complex is transient [28]. The machinery there-
fore seems to export large proteins with a substrate-responsive
pump action (Fig. 2).
While it seems evident that the myriad of small e¥ux sub-
strates could enter through the opening of the AcrB antiporter
at the cytosolic face of the inner membrane, it has been sug-
gested that substrates located in or at the membrane might
enter AcrB by other routes after association with the inner
membrane lipid bilayer [45]. The crystal structure of the AcrB
antiporter liganded with structurally diverse substrates [53]
revealed them bound at non-identical positions in the central
cavity of the transmembrane domain, but this is likely to be
only a snap-shot of an undetermined point in the e¥ux pro-
cess, especially as domain swapping has indicated that the
periplasmic domain plays a major role in substrate speci¢city
[54,55]. What seems clear is that, like proteins, drugs will be
channelled to the TolC entrance, which must be opened.
6. Twist to open ^ access to TolC by an iris-like movement of
entrance helices
Opening the periplasmic tunnel entrance is clearly key to
the function of TolC and the assembled export and e¥ux
machineries. An allosteric mechanism has been proposed for
opening, based on the observation that the three inner coiled
coils (comprising helices H7 and H8) di¡er from the outer
coiled coils (H3/H4) only by small changes in superhelical
twist [29]. It envisages that transition to the open state is
achieved by the inner coils realigning with the outer coils,
thereby enlarging the aperture diameter (Fig. 3). Comparison
of the resting closed state and modelled open state of the
entrance identi¢es three inter- and intra-molecular links that
constrain the three inner coils in the closed conformation
[29,30]. Links I and II connect each inner coiled coil to the
outer coil of the same monomer by hydrogen bonds, while
link III connects each inner coiled coil to the outer coil of the
adjacent monomer by a salt bridge and a hydrogen bond.
These links must be disrupted for the inner coiled coils to
move outwards and enlarge the entrance diameter.
We have supported this model by in vivo and in vitro ex-
periments. Formation of critical salt bridges and hydrogen
bonds was prevented by substituting the participating resi-
dues, and as the periplasmic entrance is the sole constriction
of TolC, change in the diameter of the entrance aperture was
monitored as the conductance of puri¢ed TolC proteins in
black lipid bilayers [30]. Elimination of individual connections
(I, II or III) caused incremental weakening of the circular
network, but when both components of link III were dis-
rupted simultaneously with the intra-monomer link I there
was a synergistic e¡ect, dictating a six- to 10-fold increase
over wild-type conductance. This would be compatible with
an opening aperture of 16 AS , similar to the Staphylococcus
aureus toxin [56]. The results support the model in which
transition to the open state of TolC is achieved by an iris-
like realignment of the tunnel entrance helices generating an
aperture that corresponds to the modelled open state (Fig. 3).
Complementary in vivo evidence for this opening mechanism
and its essential role in protein export was obtained by intro-
ducing disulphide bonds, directly or via a chemical cross-link-
er, to constrain entrance coiled coils [57]. Protein export from
E. coli carrying the locked TolC variants was assessed in par-
allel by monitoring the size of the entrance aperture in arti¢-
cial lipid membranes. TolC-dependent export was completely
abolished when the coiled coils were cross-linked at the nar-
Fig. 3. The closed and modelled open states of TolC. Space-¢lled
(upper) and ribbon (lower) depictions of the closed and modelled
open states of the tunnel entrance, viewed from the periplasm. The
coiled coils of one protomer are coloured (H3/4 and H7/H8, helix
numbering taken from [29]) and show the constraining intramono-
mer (I and II) and intermonomer (III) links.
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rowest point of the entrance constriction, either between ad-
jacent monomers (link A), or by connecting the inner coil of
each monomer to the outer coiled coil of its adjacent mono-
mer (link B) [57]. Although hemolysin was not exported, it
was still engaged by the type I inner membrane translocase,
and triggered recruitment of the locked TolC. Untwisting the
entrance helices is therefore essential for TolC function, and
acts speci¢cally to open the entrance to allow passage of the
substrate engaged at the inner membrane complex.
7. Pumps as drug targets ^ is it possible to block the TolC
entrance?
Knowledge of the multidrug e¥ux proteins will not only
further understanding of the mechanisms of export and e¥ux
but may facilitate design of potential antibacterial agents for
the treatment of multidrug-resistant infections. The obvious
target site is the periplasmic entrance of TolC. This is the sole
constriction in the single pore with a minimum e¡ective diam-
eter of 3.9 AS , and it is lined by a ring of six aspartate residues,
D371 and D374 from each monomer [29,58]. TolC function in
arti¢cial lipid bilayers is severely inhibited by cations entering
the channel-tunnel from the channel (‘extracellular’) side. Di-
valent and trivalent cations block the transmembrane ion £ux,
with hexamminecobalt binding at nanomolar concentrations.
When either or both of the entrance aspartates are substituted
by alanines, high-a⁄nity binding is abolished [58] and block-
ing of the membrane pore is alleviated, indicating that the
inhibitor binds to the electronegative aspartate ring. This is
supported by a crystal structure of the TolC^CoðNH3Þ6 3þ
(ligand) complex, which indicates a ligand molecule bound
at the entrance constriction (our unpublished results). This
¢rst biochemical and structural characterisation of an in vitro
inhibitor of TolC may suggest a strategy to develop bioactive
molecules, especially as the electronegative entrance is widely
conserved throughout the TolC family of Gram-negative bac-
teria.
8. The future?
Elucidating the structures of all the components of TolC-
dependent systems and de¢ning the multilateral interactions
between them and their substrates will explain how these
membrane nanomachines work. This will explain how viru-
lence protein export and multidrug e¥ux are achieved, and
perhaps suggest ways in which they might be combatted.
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